Drugs · Brain health technique
Anti-Tau Therapies (Monoclonal Antibodies)
Evidence grade: Experimental
Emerging biologics that target pathological tau aggregates to slow neurofibrillary tangle propagation. Agents under study include semorinemab (Genentech), gosuranemab (Biogen), tilavonemab (AbbVie), and BIIB076.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Emerging Longevity / Neuroregenerative Agents
- Evidence grade
- Experimental
- Strength of evidence
- Low
How to practice Anti-Tau Therapies (Monoclonal Antibodies)
Access limited to research protocols for early Alzheimer’s or tauopathies. Requires tau PET or CSF confirmation and frequent infusions with imaging follow-up. Not approved for clinical use; future trials will clarify efficacy. Participation appropriate for biomarker-confirmed early disease in specialized research centers.
The evidence behind Anti-Tau Therapies (Monoclonal Antibodies)
Tau pathology correlates more directly with cognitive decline than amyloid, making it a key therapeutic target. Early trials show good safety and biomarker engagement but minimal clinical improvement so far. Mechanism: antibodies bind extracellular tau fragments to block neuron-to-neuron spread and reduce tangle accumulation. Evidence remains early-phase, though biologically strong.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.